Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds
Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J.S., Schell, T.D., and Richie, J.P
: , bpc 157
Evaluation of the efficacy of low-level light therapy using 1072 nm infrared light for the treatment of herpes simplex labialis
FDAs Mai Tu concurred that this peptide is not well-characterized. The briefing materials also note that FDA staff has received three adverse event (AE) reports following BPC-157 injection: a 55-year-old woman reported use of BPC-157 injection and reported nine days of redness and swelling around the injection site
PMID 15823396